ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026
Phase 2 study of EBV-specific T cell therapy to be presented at a leading oncology meeting SEOUL, South Korea, April 22, 2026 /PRNewswire/ -- ViGenCell Inc. (KOSDAQ: 308080), a clinical-stage biotechnology company based in South Korea focused on...
Seegene Introduces STAgora at ESCMID Global 2026, Highlighting Real-Time Data with Automated PCR Workflows
The company highlights its approach to integrating real-time data analytics with automated PCR infrastructure The standalone booth features STAgora simulation and an interactive touchscreen experience An enhanced CURECA model is presented,...
CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
SUZHOU, China, April 20, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key...
Wondershare Brings Filmora to Microsoft's Asia Channel LINC Event to Showcase Offline AI-Powered Creative Workflows
VANCOUVER, BC, April 15, 2026 /PRNewswire/ -- Wondershare, a global leader in creative software and productivity solutions, was invited by Microsoft Corporation to participate in the Asia Channel LINC Event, where it showcased its flagship video...
Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO
CHENGDU, China, April 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that results from both the ovarian cancer cohort and the cervical cancer cohort of Phase II study...
Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
- Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of atopic dermatitis (AD) and other type 2 inflammatory...
Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
HONG KONG, March 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results of health-related quality of life (HRQoL) data (Poster: 107P) from the HARMONi-2 study at the 2026 European Lung Cancer Congress (ELCC)....
Gene Solutions Announces Strategic Entry into Türkiye with Robust Real-World Evidence at the 2nd International Hereditary Cancers Congress 2026
In Partnership with ATC Genomics, the Company Presented One of Asia's Largest Real-World Datasets (n=12,281) for AI-Powered Multi-Cancer Early Detection (MCED) and Showcased its Clinically Validated ctDNA-Powered Oncology Portfolio Across the Full...
ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference
SUZHOU, China, Feb. 27, 2026 /PRNewswire/ -- Intravesical BCG is the standard of care (SOC) for BCG-naive high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG products has become a global phenomenon, and...
The Exhibition of Achievements in Compiling A Comprehensive Collection of Ancient Chinese Paintings Opens in Hong Kong with Academic Symposium
HONG KONG, Jan. 31, 2026 /PRNewswire/ -- The Compilation of Classics in the Flourishing Age: Exhibition of Achievements in Compiling A Comprehensive Collection of Ancient Chinese Paintings is on display at the City University of Hong Kong (CityUHK)...